Prostate cancer Board decisions

The Board denied service connection for heart disease, DMII, prostate cancer, RLE and LLE peripheral neuropathy, and erectile dysfunction as they are not shown to be causally or etiologically related to any disease, injury, or incident during service.

The Veteran's claim for service connection for tinnitus was granted, while claims for initial compensable disability ratings for prostate cancer and erectile dysfunction were denied. The appeal also included a request for special monthly compensation (SMC) based on loss of use of a creative organ, which was denied.

The Board granted service connection for prostate cancer and hypertension based on the Veteran's exposure to herbicides, including Agent Orange, during his active service.

The Board remands the claims for service connection for hypertension and prostate cancer to obtain outstanding private treatment records and additional medical opinions.

The Board remands the claims for service connection for hypertension and prostate cancer to obtain outstanding private treatment records and additional medical opinions.

The Board remands the Veteran's claims for service connection for various disabilities, including bilateral hearing loss, kidney disability, congestive heart failure, residuals of stroke, prostate disability, diabetes mellitus, liver cancer, and left knee disability, to correct pre-decisional duty to assist errors.

The Board remands the claim for a VA examination to determine if the Veteran's prostate cancer is related to his military service, including exposure to contaminated water at Camp Lejeune.

The Board denied service connection for a heart disorder and prostate disorder, finding no evidence of an in-service incurrence or continuous symptoms since service.

The Board denied service connection for prostate cancer, finding no evidence of a causal relationship between the disability and the Veteran's military service, including exposure to contaminated water at Camp Lejeune.

The Board granted service connection for heart condition, hypertension, prostate cancer, and skin cancer due to in-service herbicide exposure but denied service connection for bilateral hearing loss, tinnitus, and obstructive sleep apnea.

The Board remands the claims for service connection for kidney cancer, diabetes mellitus, bladder cancer, and prostate cancer to ensure VA satisfies its duty to assist by providing a medical examination.

The Board remands the claim for service connection for prostate cancer due to pre-decisional duty to assist errors.

The Veteran's service-connected chronic lymphocytic leukemia required him to be in regular need of aid and attendance, leading to the grant of special monthly compensation (SMC) from December 27, 2022. However, an increased rating for SMC was denied.

The Board granted an effective date of April 10, 2009, for the grant of service connection for DM2, prostate cancer, erectile dysfunction associated with prostate cancer, and SMC based on loss of use of a creative organ.

The Board denied the Veteran's claim for an earlier effective date prior to February 9, 2024, for service connection of prostate cancer.

The Board granted service connection for Myelodysplastic Syndrome, Prostate Cancer, Thyroid Cancer, and Parkinson's Disease based on new and relevant evidence of exposure to toxic chemicals during active service.

The appeal of the proposed reduction of a prostate cancer disability from 100 percent to 10 percent is dismissed as a matter of law, and entitlement to a compensable rating for erectile dysfunction is denied.

The Board granted service connection for allergic rhinitis and prostate cancer under the PACT Act, but remanded claims for a right wrist disability and left achilles disability for further development.

The appeal of the proposed reduction in the evaluation for residuals of prostate cancer was dismissed as there is no specific error of fact or law at issue regarding the February 2025 proposal.

The Board granted a total disability rating based on individual unemployability (TDIU) due to service-connected disabilities and denied an increased rating for prostate cancer residuals. The appeal was dismissed or withdrawn for other claims.